Interleukin-6 (IL-6) is the major growth factor for myeloma cells and is believed to participate in the pathogenesis of chronic autoimmune diseases and postmenopausal osteoporosis. IL-6 has been recently shown to possess three topologically distinct receptor binding sites: site 1 for binding to the subunit specific chain IL-6Ra and sites 2 and 3 for the interaction with two subunits of the signaling chain gp130. We have generated a set of IL-6 variants that behave as potent cytokine receptor super-antagonists carrying substitutions that abolish interaction with gp130 at either site 2 alone (site 2 antagonist) or at both sites 2 and 3 (site 2 + 3 antagonist). In addition, substitutions have been introduced in site 1 that lead to variable increases in binding for IL-NTERLEUKIN-6 (IL-6) is a central factor for B-cell I growth and differentiation. Although the physiologic production of IL-6 is part of the development of a normal immune overproduction of this cytokine is considered to play a pathogenic role during the development of autoimmune disorders and lymphoid malignancie~.~ In multiple myeloma (MM), detectable IL-6 serum levels are constantly associated with disease a~t i v i t y~.~ and are a predictive factor in prognosis?' combined with the demonstration that the cytokine is the major growth factor for malignant plasma cells.' Although myeloma cells can sometimes produce IL-6, leading some investigators to postulate an autocrine role for this cytokine,"." its major source is a population of bone marrow (BM) stromal cells stimulated by the contact with malignant cell^.'^^'^ This evidence supports the notion that IL-6 in vivo plays a paracrine rather than an autocrine role,I4 further strenghtened by the fact that growth of myeloma cells freshly explanted from terminal patients relies on the presence of exogenously supplied IL-6." Importantly, the pathogenetic role of IL-6 in MM has been confirmed not only in transgenic mice overexpressing the cytokine,16 but also more recently in IL-6-deficient mice."
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In the light of these findings it is generally believed that IL-6 antagonism would be a valuable tool for the therapy of MM and other B-cell disorders." This is further supported by the notion that the severity of accompanying manifestations of these diseases, such as bone resorption, anemia, and acute-phase response, is positively correlated to the serum levels of IL-6.' Indeed, clinical trials with anti-IL-6 monoclonal antibodies (MoAbs) have shown significant beneficial effects of cytokine neutralization in MM, Castleman's disease, and acquired immunodeficiency syndrome (AIDS)-associated B-cell lymph~mas.~~''-~~ However, anti -IL-6 MoAbs stabilize IL-6 in the form of circulating complexes and inhibit in vivo IL-6 bioactivity only in a minority of MM patients which produce less than 16 pg/d of IL-6.23 To avoid this in vivo stabilization, an alternative therapeutic approach should be envisaged, such as the generation of IL-6 variants that block the receptor in an inactive form. IL-6 belongs to the group of helical ~ytokines.'~ Molecular modeling studies have predicted it to be similar in structure to granulocyte colony-stimulating factor (G-CSF). 25 .26 IL-6 has been shown to interact sequentially with two single-pass transmembrane receptor subunits with distinct functions, IL6Ra and g~130.'~ The first receptor chain, which binds specifically only IL-6, plays no role in the activation of signaling events and its role is that of trapping the cytokine in a form available for interaction with the signaling chain gp130." Binding of the IL-64L-6Ra complex to gp130 gives rise to a hexameric receptor complex made of two IL-6, two IL6Ra, and two gp130 subunits with a defined topology and stabilized by multiple protein-protein interaction^.^'.^^ In the hexamer each IL-6 molecule establishes contacts with two distinct gp130 chains, both of which are essential to gp130 homodimer formation and initial activation of intracytoplasmic events. These contacts are mediated by two distinct sites called 2 and 3.
Site 2 is formed by exposed residues in the IL-6 A and C helices and corresponds to a receptor binding site conserved in several helical cytokines, including growth hormone."-'* Site 3 is a composite binding site formed by residues at the beginning of the D helix spatially flanked by residues in the initial part of the A-B Amino acid
IL-6 MUTANTS INHIBIT THE GROWTH OF M M CELLS
substitutions at either of these two sites do not substantially affect binding to IL-6Ra but decrease interaction of the L-6LL-6Ra subcomplex with one of the two gp130 chains. The major consequence is impaired gp130 dimerization that results in the loss of biologic a~tivity.'~ Because IL-6 variants with these properties are still able to bind IL-6Ra efficiently, they can act as receptor antagonists on a variety of IL-6-responsive human cell lines.32 IL-6 variants carrying amino acid substitutions that improve the affinity of site 1 for L6Ra have also been generated. When these super-binder substitutions were combined with those of the antagonist, the resulting variant, named IL-6 super-antagonist, showed greater antagonistic p~tency.~'
In this report we describe the generation of additional E-6 super-antagonists with increasing affinity for L-6Ra and deficient binding to gp130 at site 2 or sites 2 + 3. These molecules were tested on a variety of IL-6-responsive cell lines, several of which were IL-6 growth-dependent myeloma cells. This confirmed that our IL-6 variant meets the requirements of being both a potent antagonist at low doses and an IL-6 inhibitor for a wide spectrum of human myeloma cell lines.
MATERIALS AND METHODS

Plasmid Construction and Expression of Proteins
All superantagonists were obtained by polymerase chain reaction (PCR). 34 In the case of Sant 5, Sant 7, and Sant 8, the regions containing the corresponding substitutions in the AB-loop were amplified using as template plasmids carrying the cDNAs encoding for hIL-6 variants D-6, A-8, and D-6/K-7,35 respectively. The primers used were designed in order to contain a 5' Bfr I site (spanning residues 38-40) and a 3' Xho I site (spanning residues 91-92).25*36 Amplified fragments were digested with Bfr I and Xho I and ligated to the pT7.7 plasmid37 carrying the Santl mutant3' digested with the same two enzymes. To construct Sant9, a 5'-xho W -N o t I fragment spanning residues 91-184 was amplified by PCR using the pT7.7/ DFRD plasmid as a template" and introduced in the pT7.7/Sant5 plasmid previously digested with the same two enzymes. The identity of all mutants was verified by DNA ~equencing.~' The sequence of the oligonucleotides used is available on request. The generation of mutants D-6, A-8, and K-71D-6 has been reported in detail elsewhere.35 Wild-type hIL-6 and its variants were produced in Escherichia coli and purified as described."
In Vitro Receptor Binding Assays
The soluble human IL-6Ra (sIL-6Ra) binding activity of hIL-6 superantagonists was assayed in enzyme-linked immunosorbent assay (EL1SA)-based binding competition experiment^.^^^^^^^ Coimmunoprecipitations of sIL-6Ra and sgpl30 in the presence of wildtype IL-6 and superantagonists were performed as de~cribed.'~
Bioassays
Hep3B. Transcriptional activation of the CRP gene promoter in the human Hep3B hepatoma cell line was determined and quantified as de~cribed.".~' A375. Cell growth was monitored by crystal violet staining as de~cribed.~' Human myeloma cell lines (HMCL). XG-1, XG-2, XG-4, and XG-6 HMCL were obtained by culturing freshly explanted malignant plasma cells from patients with terminal disease with a combination of IL-6 and granulocyte-macrophage (GM)-CSF!3 These HMCL have a plasma cell phenotype and the same Ig gene rearrangements as the patients' tumor cells. They were routinely cultured in RPMI 1640 supplemented with 5% fetal calf serum (FCS) and 1 ng/mL of recombinant IL-6.
HMCL proliferation assays. XG-1 Bioassays on XG-1 cells were performed as de~cribed.~' XG-2, XG-4 and XG-6. Cells were washed once with culture medium, incubated for 5 hours at 37°C in culture medium alone, and washed again twice. 10,OOO cells in 100 pL of culture medium were then cultured in 96-well flat-bottomed microplates for 5 days with or without 100 pg/mL of recombinant IL-6 and with graded concentrations of various IL-6 receptor antagonists. Tritiated thymidine (0.5 pCi; 25 Ci/mmoVL; CEA, Saclay, France) was added for the last 8 hours of culture, and tritiated thymidine incorporation was determined as reported el~ewhere.4~
Cells were grown at 5% COz in RPMI 1640 medium supplemented with 15% FCS and their proliferation was monitored as thymidine incorporation. Briefly, U266 cells were washed twice and then plated in 96-well microtiter plates at a density of lo4 cells/ well in RPMI 1640 and 1 % FCS. Serial dilutions of either the various antagonists or the neutralizing anti-hIL-6 MoAb CLB-IL6-8 (CLB, Amsterdam, The Netherlands) were added to each well and cells were grown in a final volume of 200 pL of culture medium for 56 hours. Eight hours before ending the culture, 1 pCi of [methyl-'HIThymidine (specific activity 83 Ci/mmol; Amersham, Slough, UK) was added to each well. Cells were then collected on glass filters and incorporated radioactivity was measured in a TopCount Microplate Scintillation Counter (Packard).
U266.
RES U LTS
Generation of a Set of IL-6 Super-Antagonists
We have recently described the generation of an L -6 receptor antagonist called DFRD, which carries the simultaneous substitution of four amino acids, two in the putative A helix Y31D/G35F and two in the putative C helix S118W V121D.32 Using specific in vitro binding assays it was possible to show that when complexed with sIL-6Ra, DFRD maintains the ability to bind a single gp130 chain but does not trigger efficient gp130 dimer f~rmation.'~ Y31, G35, S118, and V121 therefore define one site of interaction between IL-6 and gp130 which we called site 2 to distinguish it from site 1 which binds IL-6Ra (Fig l) . 32 Three aminoacid substitutions in the putative helix D were also obtained, Q1751, S176R, and Q183A (also called IRA),40345 which together increase binding affinity for IL6Ra approximately 4.5-fold:' Combining the superbinder IRA substitutions with the antagonistic DFRD gave rise to another variant, called IL-6 Sant (for super-antagonist), which was able to antagonize IL-6 bioactivity in a variety of human cell lines with a potency 8-to 10-fold higher than that of DFRD.32 Complete growth inhibition of the strictly IL-6-dependent human XG-1 myeloma cell line46 was reached with 10 pg/mL of DFRD and 1 pg/mL of IL-6-Sant, re~pectively.~' This result showed that the potency of L -6 receptor antagonists could be enhanced by increasing their affinity for IL-6Ra.
Molecular modeling of IL-6 has suggested that site 1 of interaction with IL-6Ra also comprises residues in the putative A-B loop. Indeed, we recently obtained additional su- Distribution of super-binder and antagonistic substitutions on the surface of human IL-6. Shown is a schematic RIBBONSu representation of the human 11-6 model highlighting residues that were mutated and that affect either the interaction with the hlL-6Ra (site 1) or the signal transducer gp130 (site 2 and 3). Whereas the antagonistic substitutions of the DFRD phenotype (Y31.035, S118, V121) duster in site 2 (red spheres) on helix A and C, mutations of pure super-binder character (blue spheres) are located in site 1: on Helix D, as present in 11-6 IRA (Q175, S176.01831, or within the extended region of the AB-loop (K66, A68, E69, K70, Q75, S76) connecting helix A and B. A third group of residues conferring instead a combined super-binderlantagonistic property to the molecule (L57, E59, N60, light green spheres) resides within the small helical segment in the N-terminal part of the AB-loop. Besides being super-binder," the latter mutations most likely induce local structural alterations that, because of their close proximity to site 3, affect binding to gp130.5' Also indicated are wt residues W157, D160, T162 (dark green spheres), not mutated in this work, which have been shown to constitute part of Site 3.as perbinder mutations by substituting residues 57 to 76 in the cytokine's A-B loop?* Three groups of superbinder substitutions in the A-B loop were, therefore, combined with those present in IL-6 Sant (now renamed Santl) to generate novel IL-6 super-antagonists. The list of the new variants is in Table 1 together with the type and number of substitutions introduced. Figure 1 shows the topographical localization of the substituted residues on the putative three-dimensional model of human IL-6. The Sant9 variant was also generated to assess if super-antagonism can be obtained by A-B loop mutations in the absence of the D-helix IRA superbinder substitutions. Notably, the first group of superbinder substitutions in the A-B loop, namely L57D/E59F/N6OW, map in close proximity of the region spanning residues 43-55, recently discovered to be an important structural determinant for signaling in IL-626 and shown to participate in the formation of site 3 of binding to g~1 3 0 .~~
In Vitro Binding Properties of IL-6 Super-Antagonists
IL-6 super-antagonists were expressed in E coli and their receptor binding was measured in an in vitro IL-6/IL6Ra binding assay. The results (Fig 2 and Since flag-tagged 35S-sgp130 is not recognized by the antimyc MoAb, its immunoprecipitation monitors the gp130 homodimerization. The results are in Fig 3. As expected, like the original antagonist DFRD29 none of the novel superantagonists is able to dimerize gp130 efficiently (Fig 3A) . Interestingly, Sant7 has totally lost the ability to bind gp130 (Fig 3B) , a feature characteristic of combined site 2 + 3 variants. From these results it is possible to conclude that L57/E59/N60 contribute to the efficient binding of gp130 at site 3. L57/E59/N60 reside within the small helical segment in the N-terminal part of the AB-loop (Fig 1) . Therefore, we speculate that substitution at one or more of these residues results in a local structural change that, because of its close proximity to site 3 (Fig l) , affects binding of gp130. This conclusion is further strenghtened by the observation that IL-6 mutants carrying the L57D/E59F/N6OW substitutions, but not the DFRD mutations in site 2, can still bind gp130 but do not dimerize it.35
IL-6 Super-Antagonists Show Increased Potency on a Variety of H u m n Cell Lines
IL-6 super-antagonists were tested in three different human cell lines: hepatoma Hep3B, where IL-6 induces transcription of a transfected C-reactive protein promoter4'; melanoma A375 where IL-6 induces growth arrest48; and myeloma XG-1 cells, which are dependent on IL-6 for growth.* We assayed first biologic activity in the absence of added wild-type IL-6. As expected, all variants were inactive even in high doses (not shown) as previously shown for DFRD and Santl.32 However, when tested for their ability to inhibit IL-6, they all behaved as dose-dependent antago- nists with a potency profile that mirrors the increase in the affinity for IL-6Ra (Fig 4) .
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It is worth mentioning that the absolute amount of antagonists and the relative ratio of antagonist versus wild-type (wt) IL-6 required for inhibition varies from cell line to cell line (Table 2) , probably in relation to a series of factors such as intrinsic differences in sensitivity, number of receptors, and type of assay. However, despite these variations, the SPORENO ET AL most potent super-antagonists are able to significantly affect biologic activity at doses roughly equimolar to the wt cytokine, as can be observed from the significant drop in the concentration of antagonist required to obtain 50% inhibition of IL-6 activity. Overall the most potent super-antagonists show a potency more than 100-fold higher than that of the initial antagonist DFRD, with a consequent reduction in the minimal amount required for full inhibition of XG-I myeloma cell growth from I O pg/mL for DFRD to less than 30 ng/mL for Sant8.
IL-6 Super-Antagonists Have a Wide Spectrum of Antagonism on Human Myeloma Cell Lines
To assess the spectrum of activity of IL-6 super-antagonists, they were tested on various human myeloma cell lines whose growth is dependent on IL-6. As with XG-I, XG-2, XG-4, and XG-6 have been recently derived from the peripheral blood of patients with plasma cell leukemia?3 Although XG-2 is only responsive to IL-6, XG-4 and XG-6, because of the efficient expression of the LIFR chain, can be growth stimulated also by the cytokines OncoM, LIF, and the combination of CNTF+ soluble CNTFRa, which all induce the formation of gpl30-LIFR heterodimers that activate signaling?9 The entire set of IL-6 super-antagonists was tested on both cell lines in the absence and in the presence of IL-6 and the results are shown in Fig 5. On XG-4 and XG-6 all variants were biologically inactive and behaved as dosedependent IL-6 antagonists. On the contrary, on XG-2 cells only Sant 7 was totally inactive, whereas the other molecules showed a significant, albeit strongly reduced, stimulatory growth effect. In line with this, only Sant 7 was capable of fully inhibiting growth. Worthy of note is that Sant7 differs from all the other super-antagonists because it is the only variant totally unable to interact in vitro with gp130 (Fig 2  and Table I ).
U266 myeloma cells do not depend on the addition of exogenous IL-6 for growth, but they do produce endogenous IL-6, which has been shown to stimulate cell proliferation via an autocrine loop that can be inactivated by antisense oligonucleotides to IL-6 mRNA or, less efficiently, by neutralizing antibodies to IL-6.".'" A subset of super-antagonists were tested at increasing concentrations in the absence of exogenous IL-6 and their effect was compared to that of the neutralizing MoAb8." The results (Fig 6) show that all variants tested inhibit cell growth as measured by "-thymidine incorporation. Their relative potency is comparable to that observed in other cell lines, with the most potent being Sant5 and San@ (not shown), followed by Sant 7 and then by the weak superbinder Sant 1. The extent of inhibition by IL-6 super-antagonists does not exceed 40%, a value identical to that obtained with the anti-IL-6 MoAb8.
DISCUSSION
The IL-6 receptor super-antagonists described in this report represent a class of molecules that fulfill many of the requirements for an effective neutralization of the cytokine pathogenic potential in MM. The main properties of the IL- Antagonist, ng/ml The molar excess of the various mutants necessary to give 50% inhibition in the various bioassays was calculated from inhibition curves like the ones shown in 6 super-antagonists are (1) the capacity to antagonize IL-6 at low dosage: this is an absolute prerequisite if efficient neutralization in vivo is to be achieved in MM patients where the cytokine production is of several micrograms/dayZ3; and (2) the ability to'antagonize IL-6 on a large spectrum of cytokine-responsive cells. This aspect is particularly relevant in MM where the variety of genetic changes and oncogene mutations that characterize myeloma may give rise to different cells, whose sensitivity to IL-6 diverges in both quantity and quality while still maintaining their IL-6 response.' An extreme example is represented by U266, which maintain their growth and survival via the production of endogenous IL-6 and the activation of a positive autocrine loop.LL It has to be taken into account that in these latter cells, macromolecules are expected to be only partial antagonists because they are unable to interfere with the activation of growth stimulatory pathways triggered by the fraction of IL-6 that interacts with its receptors inside the endoplasmic reticulum. Indeed, it has been previously shown that antisense oligonucleotides to IL-6 mRNA are more efficient growth inhibitors than antibodies to the cytokine." Therefore, as anticipated we find that the maximum degree of inhibition is identical for IL-6 super-antagonists and antibodies to IL-6. In accordance with the expectations, the entire class of site 2 IL-6 super-antagonists is capable of fully antagonizing IL-6 in all tested cell lines, with the exception of XG-2. However, in this cell line full antagonism is obtained with the site 2 + 3 variant Sant7. Therefore, site 2 + 3 antagonism appears as the feature required to avoid leakage effects and a possible weak agonistic behavior on a minority, although certainly not negligible, population of MM cells. In conclusion, Sant7 thus represents a possible candidate for blocking IL-6 in vivo because it combines both potency and wide spectrum efficacy.
At the present time, we cannot provide a clear explanation for the different behavior of the super-antagonists on the various IL-6-responsive cell lines. The observed discrepancies are basically of two types: the fact that site 2 antagonists may seldom be ineffective (as discussed above for XG-2 cells) and the evidence that in the cell lines inhibitable by the entire class of molecules, their relative potency is not always identical; for example, Sant7 is more potent than Sant5 on XG-4 cells, equally potent on XG-6, but significantly less on XG-1, Hep3B, and A375 cells. This is likely to somehow mirror the biologic heterogeneity of the different cells. For myeloma cells, in particular, there is abundant evidence that they can vary in the number of IL-6 receptors and receptor recycling, in the production of soluble and biologically active IL-6Ra, in the coexpression of other receptor chains that may cooperate with gp130 to induce cell g r~w t h~~~ and sometimes may accumulate genetic changes in both IL6Ra and g~1 3 0 ,~~ whose consequences for receptor assembly and signalling have not yet been fully explored. Therefore, For personal use only. on October 27, 2017. by guest www.bloodjournal.org From
Antagonists or anti-hIL-6 mAb8 [ng/mll it is likely that one or more of these factors contribute to the different behavior of IL-6 super-antagonists on XG cells. In this context, the group of IL-6 super-antagonists we have generated will certainly constitute valuable tools to analyze, dissect, and understand diversity in myeloma, a goal that cannot be achieved with monoclonals directed either against the cytokine or its receptor chains.
Together with its role as growth factor for MM cells, IL-6 also prevents normal and malignant plasma cells from undergoing a p o p t o s i~.~~~~~ Although in vivo only a minor fraction of myeloma cells (1% to 5%) proliferates and IL-6 controls this growth, it is reasonable to speculate that survival of nonproliferating MM cells also depends on the same cytokine, which is known to increase the ratio of anti-apoptotic (bcl-2 and bcl-x,) versus proapoptotic (bax) protein~?~." The anti-apoptotic role of IL-6 is probably also important for the establishment of chemoresistance. IL-6 has been recently shown to inhibit dexamethasone-induced apoptosis in myeloma cells." This, together with the evidence that the cytokine can upregulate glutathione S-transferase expression and chemoresistance to cytotoxic agents," provides a reasonable explanation for the limited efficacy of the present chemotherapeutic protocols used in this disease. Therefore, the dual role of IL-6 as survival and growth factor in MM emphasizes the need for IL-6 antagonists. The molecules described in this report block IL-6 access to the receptor, should not stabilize the cytokine and, therefore, may act synergistically with melphalan and corticosteroids to induce myeloma cell death. Although we have not directly explored this issue, this is certainly open to investigation in suitable in vitro and in vivo models.
The recent study by Lu et a123 has led to two important conclusions. First, MoAbs to IL-6 stabilize the cytokine in a form biologically able to activate the membrane-bound receptors and are not able to reach therapeutic dosages in high IL-6 producers. Secondly, the daily production of IL-6 in MM patients was estimated, and resulted to be often up to 100 pgld. IL-6 super-antagonists have a pharmacologic mechanism opposite to anti-IL-6 monoclonals and are therefore expected to leave the clearance of the wt cytokine unchanged. Furthermore, although it is not possible to make a precise calculation of the amount of super-antagonist required for full IL-6 inhibition in vivo, because this largely depends on still unknown pharmacokinetic properties and distribution, the potency displayed in vitro allows the prediction that effective dosages could be achieved also in patients with elevated production of the cytokine.
Finally, although in the present study we carefully analyze the effect of IL-6 super-antagonists on myeloma cells and discuss in detail their potential use for the therapy of MM, we should bear in mind that IL-6 has been shown to play a pathogenic role in several other disease such as lupus erythematosus, rheumatoid arthritis, and postmenopausal osteoporosis: In the light of this evidence and in view of the wide spectrum of activity of IL-6 super-antagonists, future efforts wilt have to be directed to assess their effect on a variety of other pathologies using suitable in vitro and in vivo models.
